Bullfrog AI Closes $3.13 Million Offering and Placement
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) is excited to announce the closure of its recent registered direct offering along with a concurrent private placement. This strategic move is aimed at bolstering their innovative drug development pipeline that leverages cutting-edge artificial intelligence (AI) and machine learning.
Details of the Offering
The direct offering comprised 1,565,000 shares of common stock, along with associated warrants to purchase the same amount of shares. The total gross proceeds from this offering are expected to reach around $3.13 million. This figure does not include additional funds that may be generated from the future exercise of these warrants.
Warrant Details
The warrants attached to the offering come with an exercise price set at $2.00 per share. Investors will be able to exercise the warrants starting six months following their issuance, with an expiration period of five years thereafter. This strategic arrangement enhances the long-term potential for all parties involved.
Strategic Role of WallachBeth Capital
WallachBeth Capital, LLC played a crucial role as the sole placement agent for both the registered direct offering and the private placement. Their expertise in the financial sector supports organizations like Bullfrog AI in raising necessary funds for ongoing and future projects.
Registration and Compliance
It’s important to note that the shares of common stock and associated pre-funded warrants were issued based on an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC). This ensures that everything complies with the applicable regulatory framework, allowing for streamlined processes moving forward.
Future Developments
The growth of Bullfrog AI is not just a singular event but part of ongoing efforts to innovate in the pharmaceutical space. The funds raised through this offering will be crucial for enhancing research capabilities and supporting new developments within the company’s pipeline.
About Bullfrog AI
Bullfrog AI is not your average pharmaceutical entity. This unique company stands at the intersection of technology and medicine, utilizing its proprietary bfLEAP(TM) platform to revolutionize drug development processes. By analyzing vast networks of biological, clinical, and real-world data, Bullfrog AI aims to significantly reduce development costs and improve success rates for new therapeutics.
Collaborations and Innovations
The company collaborates with leading research institutions to harness AI effectively in drug development, ensuring that their approaches are cutting-edge and effective. By streamlining data analytics, they hold the potential to transform how pharmaceuticals are brought to market, making the exploration of new treatments more efficient and effective.
Contact Information
For further inquiries or detailed information regarding Bullfrog AI and its innovative approaches in drug development, folks can reach out to:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
Frequently Asked Questions
What was the total gross amount raised in the offering?
The overall gross proceeds from the offering were approximately $3.13 million.
What is the exercise price for the warrants issued?
The exercise price is set at $2.00 per share.
Who acted as the placement agent for the offering?
WallachBeth Capital, LLC served as the sole placement agent for the registered direct offering and private placement.
What technology does Bullfrog AI use for drug development?
Bullfrog AI uses artificial intelligence and machine learning, particularly its bfLEAP(TM) platform, to enhance pharmaceutical development.
How do the funds from the offering benefit Bullfrog AI?
The raised funds will support ongoing research and innovation in drug development, enabling the company to enhance its pipeline and efficiency.
